This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.
Stay current with the best on medical education
